{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:27:56Z","timestamp":1789043276879,"version":"build-2803163510"},"reference-count":211,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["5NU2RGH001915-04-00"],"award-info":[{"award-number":["5NU2RGH001915-04-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Continued investment in the development and application of mathematical models of poliovirus transmission, economics, and risks leads to their use in support of polio endgame strategy development and risk management policies. This study complements an earlier review covering the period 2000\u20132019 and discusses the evolution of studies published since 2020 by modeling groups supported by the Global Polio Eradication Initiative (GPEI) partners and others. We systematically review modeling papers published in English in peer-reviewed journals from 2020\u20132024.25 that focus on poliovirus transmission and health economic analyses. In spite of the long-anticipated end of poliovirus transmission and the GPEI sunset, which would lead to the end of its support for modeling, we find that the number of modeling groups supported by GPEI partners doubled and the rate of their publications increased. Modeling continued to play a role in supporting GPEI and national\/regional policies, but changes in polio eradication governance, decentralized management and decision-making, and increased heterogeneity in modeling approaches and findings decreased the overall impact of modeling results. Meanwhile, the failure of the 2016 globally coordinated cessation of type 2 oral poliovirus vaccine use for preventive immunization and the introduction of new poliovirus vaccines and formulation, increased the complexity and uncertainty of poliovirus transmission and economic models and policy recommendations during this time.<\/jats:p>","DOI":"10.3390\/pathogens13060435","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T07:56:11Z","timestamp":1716364571000},"page":"435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020\u20132024"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-9147","authenticated-orcid":false,"given":"Kimberly M.","family":"Thompson","sequence":"first","affiliation":[{"name":"Kid Risk, Inc., Orlando, FL 32819, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-9455","authenticated-orcid":false,"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[{"name":"Kid Risk, Inc., Orlando, FL 32819, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/14760584.2020.1791093","article-title":"Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication","volume":"19","author":"Thompson","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14760584.2020.1732215","article-title":"The potential role of using vaccine patches to induce immunity: Platform and pathways to innovation and commercialization","volume":"19","author":"Badizadegan","year":"2020","journal-title":"Expert Rev. Vaccines"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.vaccine.2020.01.042","article-title":"Performance of the United States Vaccine Injury Compensation Program (VICP): 1988\u20132019","volume":"38","author":"Thompson","year":"2020","journal-title":"Vaccine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1016\/j.vaccine.2020.04.044","article-title":"An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches","volume":"38","author":"Thompson","year":"2020","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/14737167.2020.1812387","article-title":"Valuing health outcomes: Developing better defaults based on health opportunity costs","volume":"21","author":"Ochalek","year":"2021","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/risa.13668","article-title":"Modeling and managing poliovirus risks: We are where we are","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/risa.13447","article-title":"Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/risa.13484","article-title":"Reflections on modeling poliovirus transmission and the polio eradication endgame","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/risa.13471","article-title":"Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/risa.13485","article-title":"Modeling poliovirus transmission in Borno and Yobe, Northeast Nigeria","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/risa.13486","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in Northeast Nigeria","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/risa.13555","article-title":"Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/risa.13557","article-title":"Potential future use, costs, and value of poliovirus vaccines","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/risa.13590","article-title":"Expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/risa.13622","article-title":"Updated characterization of outbreak response strategies for 2019\u20132029: Impacts of using a novel type 2 oral poliovirus vaccine strain","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(20)32629-5","article-title":"Poliovirus vaccine options: Another step forward","volume":"397","author":"Thompson","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/risa.13665","article-title":"An updated economic analysis of the Global Polio Eradication Initiative","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/risa.13664","article-title":"Health and economic outcomes associated with polio vaccine policy options: 2019\u20132029","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Risk Anal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/risa.13614","article-title":"A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"A12","DOI":"10.1016\/j.vaccine.2021.04.026","article-title":"The impact of disruptions caused by the COVID-19 pandemic on global polio eradication","volume":"41","author":"Kalkowska","year":"2021","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1080\/14760584.2021.1891888","article-title":"Hypothetical emergence of poliovirus in 2020: Part 1. consequences of policy decisions to respond using nonpharmaceutical interventions","volume":"20","author":"Thompson","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/14760584.2021.1891889","article-title":"Hypothetical emergence of poliovirus in 2020: Part 2. exploration of the potential role of vaccines in control and eradication","volume":"20","author":"Thompson","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/infdis\/jiab160","article-title":"Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options","volume":"224","author":"Kalkowska","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ofab264","DOI":"10.1093\/ofid\/ofab264","article-title":"Modeling Poliovirus Surveillance and Immunization Campaign Quality Monitoring Costs for Pakistan and Afghanistan for 2019\u20132023","volume":"8","author":"Kalkowska","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"A136","DOI":"10.1016\/j.vaccine.2021.04.061","article-title":"Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(21)00458-8","article-title":"Polio eradication: What kind of world do we want?","volume":"22","author":"Thompson","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1697","DOI":"10.1016\/S2214-109X(22)00452-1","article-title":"Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame","volume":"10","author":"Thompson","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/14760584.2022.2017287","article-title":"Health economic analyses of secondary vaccine effects: A systematic review and policy insights","volume":"21","author":"Thompson","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12688\/gatesopenres.13524.1","article-title":"Polio health economics: Assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative","volume":"6","author":"Thompson","year":"2022","journal-title":"Gates Open Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/infdis\/jiac130","article-title":"Polio by the numbers\u2014A global perspective","volume":"226","author":"Badizadegan","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1080\/14760584.2022.2128108","article-title":"Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036","volume":"21","author":"Thompson","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/risa.13983","article-title":"Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan","volume":"43","author":"Kalkowska","year":"2023","journal-title":"Risk Anal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/risa.13982","article-title":"Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan","volume":"43","author":"Kalkowska","year":"2023","journal-title":"Risk Anal."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"A142","DOI":"10.1016\/j.vaccine.2022.10.060","article-title":"Outbreak response strategies with type 2-containing oral poliovirus vaccines","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2023.04.037","article-title":"Outbreak management strategies for cocirculation of multiple poliovirus types","volume":"41","author":"Kalkowska","year":"2023","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1098419","DOI":"10.3389\/fpubh.2023.1098419","article-title":"Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation","volume":"11","author":"Thompson","year":"2023","journal-title":"Front. Public Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.12688\/gatesopenres.14511.1","article-title":"Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation","volume":"7","author":"Kalkowska","year":"2023","journal-title":"Gates Open Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2022.12.021","article-title":"Polio eradication: Addressing the hurdles on the last mile","volume":"186","author":"Thompson","year":"2023","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S1473-3099(23)00133-0","article-title":"Polio endgame complexity: Updating expectations for nOPV2","volume":"23","author":"Thompson","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/14760584.2023.2263096","article-title":"Oral polio vaccine stockpile modeling: Insights from recent experience","volume":"22","author":"Thompson","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/risa.14158","article-title":"Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences","volume":"44","author":"Kalkowska","year":"2023","journal-title":"Risk Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/risa.14159","article-title":"Worst-case scenarios: Modeling uncontrolled type 2 polio transmission","volume":"44","author":"Kalkowska","year":"2023","journal-title":"Risk Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1177\/0272989X231191127","article-title":"Health economic analysis of antiviral drugs in the global polio eradication endgame","volume":"43","author":"Badizadegan","year":"2023","journal-title":"Med. Decis. Mak."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/infdis\/jiad355","article-title":"Modeling poliovirus transmission and responses in New York State","volume":"229","author":"Thompson","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/14760584.2023.2299401","article-title":"Modeling undetected poliovirus circulation following the 2022 outbreak in the United States","volume":"23","author":"Kalkowska","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.vaccine.2023.12.081","article-title":"Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization","volume":"42","author":"Thompson","year":"2024","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"A93","DOI":"10.1016\/j.vaccine.2021.09.037","article-title":"Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic","volume":"41","author":"Molodecky","year":"2023","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.vaccine.2021.03.001","article-title":"Quantifying movement patterns and vaccination status of high risk mobile populations in Pakistan and Afghanistan to inform poliovirus risk and vaccination strategy","volume":"39","author":"Molodecky","year":"2021","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41541-020-0178-5","article-title":"Immune predictors of oral poliovirus vaccine immunogenicity among infants in South India","volume":"5","author":"Babji","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"veaa040","DOI":"10.1093\/ve\/veaa040","article-title":"The role of genetic sequencing and analysis in the polio eradication programme","volume":"6","author":"Jorgensen","year":"2020","journal-title":"Virus Evol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/infdis\/jiaa175","article-title":"Characterizing environmental surveillance sites in Nigeria and their sensitivity to detect poliovirus and other enteroviruses","volume":"225","author":"Hamisu","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(21)00453-9","article-title":"Risk factors for spread of vaccine-derived type 2 polioviruses in Africa following global withdrawal of trivalent oral poliovirus vaccine and impact of outbreak response with monovalent vaccine: A retrospective analysis of surveillance data","volume":"22","author":"Cooper","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiad004","article-title":"The origins and risk factors for serotype-2 vaccine-derived poliovirus (VDPV2) emergences in Africa during 2016\u20132019","volume":"228","author":"Gray","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.vaccine.2023.01.035","article-title":"Effect of maternal immunisation with multivalent vaccines containing inactivated poliovirus vaccine (IPV) on infant IPV immune response: A phase 4, multi-centre randomised trial","volume":"41","author":"Grassly","year":"2023","journal-title":"Vaccine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(23)00688-6","article-title":"Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: A case-control study","volume":"24","author":"Cooper","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0140-6736(24)00053-9","article-title":"First Africa-based clinical trial for novel type 2 oral poliovirus vaccine","volume":"403","author":"Cooper","year":"2024","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Bandyopadhyay, A.S., Cooper, L.V., and Zipursky, S. (2024). One billion doses and WHO prequalification of nOPV2: Implications for the global polio situation and beyond. PLOS Glob. Public Health, 4.","DOI":"10.1371\/journal.pgph.0002920"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kurji, F.D., Bandyopadhyay, A.S., Zipursky, S., Cooper, L.V., Gast, C., Toher, M., Clemens, R., Clemens, S.A.C., Prasad, R., and Azhari, A. (2024). Novel oral polio vaccine type 2 use for polio outbreak response: A global effort for a global health emergency. Pathogens, 13.","DOI":"10.3390\/pathogens13040273"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10-1128","DOI":"10.1128\/JCM.00920-20","article-title":"Rapid and sensitive direct detection and identification of poliovirus from stool and environmental surveillance samples by use of nanopore sequencing","volume":"58","author":"Shaw","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/infdis\/jiab518","article-title":"Time taken to detect and respond to polio outbreaks in Africa and the potential impact of direct molecular detection and nanopore sequencing","volume":"226","author":"Shaw","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Akello, J.O., Bujaki, E., Shaw, A.G., Khurshid, A., Arshad, Y., Troman, C., Majumdar, M., O\u2019Toole, A., Rambaut, A., and Alam, M.M. (2023). Comparison of eleven RNA extraction methods for poliovirus direct molecular detection in stool samples. Microbiol. Spectr., 11.","DOI":"10.1128\/spectrum.04252-22"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41564-023-01453-4","article-title":"Sensitive poliovirus detection using nested PCR and nanopore sequencing: A prospective validation study","volume":"8","author":"Shaw","year":"2023","journal-title":"Nat. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-023-02457-7","article-title":"Defining a research agenda for environmental wastewater surveillance of pathogens","volume":"29","author":"Shaw","year":"2023","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"o1589","DOI":"10.1136\/bmj.o1589","article-title":"Polio\u2019s detection in London is a wake-up call","volume":"377","author":"Grassly","year":"2022","journal-title":"BMJ"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(22)01804-9","article-title":"Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance","volume":"400","author":"Klapsa","year":"2022","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1473-3099(23)00505-4","article-title":"Use of inactivated poliovirus vaccine for poliovirus outbreak response","volume":"24","author":"Bandyopadhyay","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Vallejo, C., Pearson, C.A.B., Koopman, J.S., and Hladish, T.J. (2022). Effect of population partitioning on the probability of silent circulation of poliovirus. Bull. Math. Biol., 84.","DOI":"10.1007\/s11538-022-01014-6"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1126\/science.aba1238","article-title":"Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine","volume":"368","author":"Macklin","year":"2020","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1017\/S0950268820001004","article-title":"Surveillance optimisation to detect poliovirus in the pre-eradication era: A modelling study of England and Wales","volume":"148","author":"Grassly","year":"2020","journal-title":"Epidemiol. Infect."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"A19","DOI":"10.1016\/j.vaccine.2022.08.008","article-title":"Epidemiology of type 2 vaccine-derived poliovirus outbreaks between 2016 and 2020","volume":"41","author":"Macklin","year":"2023","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.12688\/gatesopenres.13272.1","article-title":"The impact of surveillance and other factors on detection of emergent and circulating vaccine derived polioviruses","volume":"5","author":"Auzenbergs","year":"2021","journal-title":"Gates Open Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/QCO.0000000000000667","article-title":"Final frontiers of the polio eradication endgame","volume":"33","author":"Bandyopadhyay","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"A122","DOI":"10.1016\/j.vaccine.2022.02.050","article-title":"Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel oral polio vaccine type 2 (nOPV2) experience","volume":"41","author":"Macklin","year":"2023","journal-title":"Vaccine"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Fine, P.E.M. (2024). Population immunity and polio eradication. Pathogens, 13.","DOI":"10.3390\/pathogens13030183"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/S2666-5247(20)30100-2","article-title":"The challenges of informative wastewater sampling for SARS-CoV-2 must be met: Lessons from polio eradication","volume":"1","author":"Allen","year":"2020","journal-title":"Lancet Microbe"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/infdis\/jiaa390","article-title":"A randomized phase 4 study of immunogenicity and safety after monovalent oral type 2 Sabin poliovirus vaccine challenge in children vaccinated with inactivated poliovirus vaccine in Lithuania","volume":"223","author":"Bandyopadhyay","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/infdis\/jiaa783","article-title":"Intestinal antibody responses to 2 novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium","volume":"226","author":"Brickley","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41385-021-00428-0","article-title":"Mucosal immunity to poliovirus","volume":"15","author":"Connor","year":"2022","journal-title":"Mucosal Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Famulare, M., Wong, W., Haque, R., Platts-Mills, J.A., Saha, P., Aziz, A.B., Ahmed, T., Islam, M.O., Uddin, M.J., and Bandyopadhyay, A.S. (2021). Multiscale model for forecasting Sabin 2 vaccine virus household and community transmission. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1009690"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"vead044","DOI":"10.1093\/ve\/vead044","article-title":"From vaccine to pathogen: Modeling Sabin 2 vaccine virus reversion and evolutionary epidemiology in Matlab, Bangladesh","volume":"9","author":"Wong","year":"2023","journal-title":"Virus Evol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"20220006","DOI":"10.1098\/rsif.2022.0006","article-title":"The role of time-varying viral shedding in modelling environmental surveillance for public health: Revisiting the 2013 poliovirus outbreak in Israel","volume":"19","author":"Brouwer","year":"2022","journal-title":"J. R. Soc. Interface"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chom.2020.10.011","article-title":"The early evolution of oral poliovirus vaccine Is shaped by strong positive selection and tight transmission bottlenecks","volume":"29","author":"Valesano","year":"2021","journal-title":"Cell Host Microbe"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/risa.13580","article-title":"Disease surveillance investments and administration: Limits to information value in Pakistan polio eradication","volume":"41","author":"Scott","year":"2021","journal-title":"Risk Anal."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1016\/j.vaccine.2021.08.064","article-title":"Real-time prediction model of cVDPV2 outbreaks to aid outbreak response vaccination strategies","volume":"41","author":"Voorman","year":"2023","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"A85","DOI":"10.1016\/j.vaccine.2022.03.013","article-title":"Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine","volume":"41","author":"Voorman","year":"2023","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/infdis\/jiad222","article-title":"Impact of supplementary immunization activities using novel oral polio vaccine type 2 during a large outbreak of circulating vaccine-derived poliovirus in Nigeria","volume":"229","author":"Voorman","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Sun, Y., Keskinocak, P., Steimle, L.N., Kovacs, S.D., and Wassilak, S.G. (2023, January 10\u201313). A compartmental simulation model to improve interventions for controlling poliovirus outbreaks. Proceedings of the 2023 Winter Simulation Conference (WSC), San Antonio, TX, USA.","DOI":"10.1109\/WSC60868.2023.10407506"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100476","DOI":"10.1016\/j.jvacx.2024.100476","article-title":"Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria","volume":"18","author":"Sun","year":"2024","journal-title":"Vaccine X"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Cheng, E., Gambhirrao, N., Patel, R., Zhowandai, A., Rycht\u00e1\u0159, J., and Taylor, D. (2020). A game-theoretical analysis of poliomyelitis vaccination. J. Theor. Biol., 499.","DOI":"10.1016\/j.jtbi.2020.110298"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"13138","DOI":"10.1073\/pnas.1922746117","article-title":"Prosocial polio vaccination in Israel","volume":"117","author":"Wells","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Ren, J., Maimaiti, H., Sun, X., Huang, Z., Liu, J., Yang, J., Li, Z., Bai, Q., and Lu, Y. (2021). Cost-effectiveness of three poliovirus immunization schedules in Shanghai, China. Vaccines, 9.","DOI":"10.3390\/vaccines9101062"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"990042","DOI":"10.3389\/fpubh.2022.990042","article-title":"Cost-effectiveness of various immunization schedules with inactivated Sabin strain polio vaccine in Hangzhou, China","volume":"10","author":"Xu","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"967920","DOI":"10.3389\/fpubh.2022.967920","article-title":"One vaccine to counter many diseases? Modeling the economics of oral polio vaccine against child mortality and COVID-19","volume":"10","author":"Chang","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ahmed, N., Macias-Diaz, J.E., Shahid, N., Raza, A., and Rafiq, M. (2022). A dynamically consistent computational method to solve numerically a mathematical model of polio propagation with spatial diffusion. Comput. Methods Programs Biomed., 218.","DOI":"10.1016\/j.cmpb.2022.106709"},{"key":"ref_95","first-page":"2357","article-title":"Bio-inspired computational methods for the polio virus epidemic model","volume":"72","author":"Alrawajeh","year":"2022","journal-title":"CMC-Comput. Mater. Contin."},{"key":"ref_96","first-page":"17","article-title":"Fractional mathematical modeling to the spread of polio with the role of vaccination under non-singular kernal","volume":"30","author":"Liu","year":"2022","journal-title":"Fractals-Complex Geom. Patterns Scaling Nat. Soc."},{"key":"ref_97","first-page":"3415","article-title":"Treatment of polio delayed epidemic model via computer simulations","volume":"70","author":"Naveed","year":"2022","journal-title":"CMC-Comput. Mater. Contin."},{"key":"ref_98","first-page":"257","article-title":"Stochastic analysis for the dynamics of a poliovirus epidemic model","volume":"136","author":"Raza","year":"2022","journal-title":"CMES-Comput. Model. Eng. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1515\/ijnsns-2020-0149","article-title":"Mathematical analysis of the impact of vaccination and poor sanitation on the dynamics of poliomyelitis","volume":"24","author":"Bornaa","year":"2023","journal-title":"Int. J. Nonlinear Sci. Numer. Simul."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.aej.2022.08.025","article-title":"Analysis of the fractional polio model with the Mittag-Leffler kernels","volume":"64","author":"Iqbal","year":"2023","journal-title":"Alex. Eng. J."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8175","DOI":"10.1002\/mma.7607","article-title":"Numerical analysis of polio model: A mathematical approach to epidemiological model using derivative with Mittag-Leffler Kernel","volume":"46","author":"Karaagac","year":"2023","journal-title":"Math. Methods Appl. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cnsns.2022.107009","article-title":"Spreading speeds in two reaction-diffusion models for polio disease","volume":"118","author":"Wang","year":"2023","journal-title":"Commun. Nonlinear Sci. Numer. Simul."},{"key":"ref_103","unstructured":"World Health Assembly (1988). Global Eradication of Poliomyelitis by the Year 2000, World Health Organization."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Thompson, K.M., and Badizadegan, K. (Expert Rev. Vaccines, 2024). Evolution of global polio eradication strategies: Targets, vaccines, and supplemental immunization activities (SIAs), Expert Rev. Vaccines, Submitted.","DOI":"10.1080\/14760584.2024.2361060"},{"key":"ref_105","unstructured":"World Health Organization (2000). Vaccines & Biologicals Annual Report 1999, World Health Organization."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/oxfordjournals.epirev.a036121","article-title":"Herd immunity: History, theory, practice","volume":"15","author":"Fine","year":"1993","journal-title":"Epidemiol. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/oxfordjournals.aje.a009924","article-title":"Transmissibility and persistence of oral polio vaccine viruses: Implications for the global poliomyelitis eradication initiative","volume":"150","author":"Fine","year":"1999","journal-title":"Am. J. Epidemiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0025-5564(94)00046-3","article-title":"Deterministic models for the eradication of poliomyelitis: Vaccination with the inactivated (IPV) and attenuated (OPV) polio virus vaccine","volume":"127","author":"Eichner","year":"1995","journal-title":"Math. Biosci."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Isham, V., and Medley, G.F. (1996). Models for Infectious Human Diseases: Their Structure and Relation to Data, Cambridge University Press.","DOI":"10.1017\/CBO9780511662935"},{"key":"ref_110","first-page":"35","article-title":"Global eradication of poliomyelitis: Benefit-cost analysis","volume":"74","author":"Bart","year":"1996","journal-title":"Bull. World Health Organ."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, K.M., Verity, R., Durry, E., Asghar, H., Sharif, S., Zaidi, S.Z., Wadood, M.Z.M., Diop, O.M., Okayasu, H., and Safdar, R.M. (2018). Population sensitivity of acute flaccid paralysis and environmental surveillance for serotype 1 poliovirus in Pakistan: An observational study. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3070-4"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S1473-3099(19)30301-9","article-title":"Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: A systematic review and network meta-analysis","volume":"19","author":"Macklin","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_113","first-page":"129","article-title":"Stopping a polio outbreak in the post-eradication era","volume":"105","author":"Fine","year":"2001","journal-title":"Dev. Biol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Wringe, A., Fine, P.E., Sutter, R.W., and Kew, O.M. (2008). Estimating the extent of vaccine-derived poliovirus infection. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003433"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-induced mucosal immunity to poliovirus: Analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e001613","DOI":"10.1136\/bmjgh-2019-001613","article-title":"Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden","volume":"4","author":"Brickley","year":"2019","journal-title":"BMJ Glob. Health"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/cid\/ciy603","article-title":"Intestinal immunity to poliovirus following sequential trivalent inactivated polio vaccine\/bivalent oral polio vaccine and trivalent inactivated polio vaccine-only immunization schedules: Analysis of an open-label, randomized, controlled trial in Chilean infants","volume":"67","author":"Brickley","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_119","first-page":"358","article-title":"Gaps in our knowledge about transmission of vaccine-derived polioviruses","volume":"78","author":"Fine","year":"2000","journal-title":"Bull. World Health Organ."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.1071207","article-title":"Virology. Poliomyelitis eradication\u2014A dangerous endgame","volume":"296","author":"Nathanson","year":"2002","journal-title":"Science"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/j.1539-6924.2006.00855.x","article-title":"Perspective: Determinants of the severity of poliovirus outbreaks in the post eradication era","volume":"26","author":"Fine","year":"2006","journal-title":"Risk Anal."},{"key":"ref_122","first-page":"47","article-title":"Polio control after certification: Major issues outstanding","volume":"82","author":"Fine","year":"2004","journal-title":"Bull. World Health Organ."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S1474-4422(04)00928-7","article-title":"Poliomyelitis: Very small risks and very large risks","volume":"3","author":"Fine","year":"2004","journal-title":"Lancet Neurol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(07)60533-9","article-title":"Global poliomyelitis eradication: Status and implications","volume":"369","author":"Fine","year":"2007","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/605331","article-title":"Polio: Measuring the protection that matters most","volume":"200","author":"Fine","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_126","first-page":"1439","article-title":"Commentary: An unexpected finding that needs confirmation or rejection","volume":"321","author":"Fine","year":"2000","journal-title":"BMJ"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S1473-3099(17)30236-0","article-title":"Maximising the impact of inactivated polio vaccines","volume":"17","author":"Brickley","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1016\/j.vaccine.2017.08.063","article-title":"Polio immunity and the impact of mass immunization campaigns in the Democratic Republic of the Congo","volume":"35","author":"Voorman","year":"2017","journal-title":"Vaccine"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Alfonso, V.H., Voorman, A., Hoff, N.A., Weldon, W.C., Gerber, S., Gadoth, A., Halbrook, M., Goldsmith, A., Mukadi, P., and Doshi, R.H. (2022). Poliovirus immunity among adults in the Democratic Republic of the Congo: A cross-sectional serosurvey. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-021-06951-6"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.jvacx.2020.100067","article-title":"Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan","volume":"5","author":"Voorman","year":"2020","journal-title":"Vaccine X"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.jvacx.2020.100059","article-title":"New analytic approaches for analyzing and presenting polio surveillance data to supplement standard performance indicators","volume":"4","author":"VanderEnde","year":"2020","journal-title":"Vaccine X"},{"key":"ref_132","unstructured":"World Health Organization (2024, March 28). Strategic Advisory Group of Experts on Immunization Meetings. Available online: https:\/\/www.who.int\/groups\/strategic-advisory-group-of-experts-on-immunization\/meetings."},{"key":"ref_133","unstructured":"Global Polio Eradication Initiative (2023, November 13). Progress 1999: Every Child Counts. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/66964\/WHO_POLIO_00.03.pdf."},{"key":"ref_134","unstructured":"Global Polio Eradication Initiative (2023, November 13). Progress 2000. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/66763\/WHO_POLIO_01.03.pdf."},{"key":"ref_135","unstructured":"Global Polio Eradication Initiative (2023, November 13). Progress 2001. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/67417\/WHO_POLIO_02.08.pd."},{"key":"ref_136","unstructured":"Global Polio Eradication Initiative (2023, November 13). Progress 2002. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/67931\/WHO_POLIO_03.02.pdf."},{"key":"ref_137","unstructured":"Global Polio Eradication Initiative (2023, November 13). Progress 2003. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/68653\/WHO_POLIO_04.02.pdf."},{"key":"ref_138","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2004 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/69055\/WHO_POLIO_05.03.pdf."},{"key":"ref_139","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2005 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70869\/WHO_Polio_06.02_eng.pdf."},{"key":"ref_140","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2006 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70868\/WHO_Polio_07.02_eng.pdf."},{"key":"ref_141","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2007 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70867\/WHO_Polio_08.02_eng.pdf."},{"key":"ref_142","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2008 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70866\/WHO_POLIO_09.03_eng.pdf."},{"key":"ref_143","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2009 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70865\/WHO_Polio_10.05_eng.pdf."},{"key":"ref_144","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2010 Annual Report: Every Last Child. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/70849\/WHO_POLIO_11.02_eng.pdf."},{"key":"ref_145","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2011 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276243\/WHO-POLIO-12.02-eng.pdf."},{"key":"ref_146","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2012 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276241\/WHO-POLIO-13.03-eng.pdf."},{"key":"ref_147","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2013 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276239\/WHO-POLIO-14.02-eng.pdf."},{"key":"ref_148","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2014 Annual Report: On the Threshold of a Polio Free World. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276238\/WHO-POLIO-15.01-eng.pdf."},{"key":"ref_149","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2015 Annual Report: Eradication within Reach. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/250145\/WHO-POLIO-16.01-eng.pdf."},{"key":"ref_150","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2016 Annual Report: Eradication within Reach. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276236\/WHO-POLIO-17.03-eng.pdf."},{"key":"ref_151","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2017 Annual Report: Securing a Lasting World Free of All Polioviruses. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/276237\/WHO-POLIO-18.01-eng.pdf."},{"key":"ref_152","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2018 Annual Report: To Achieve Lasting Success. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/Annual-report-2018.pdf."},{"key":"ref_153","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2019 Annual Report and Semi-Annual Status Updates, January\u2013June and July\u2013December 2019. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/336693\/9789240013117-eng.pdf."},{"key":"ref_154","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2020 Annual Report and Semi-Annual Status Updates, January\u2013June and July\u2013December 2020. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/344329\/9789240030763-eng.pdf."},{"key":"ref_155","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2021 Annual Report. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/364215\/9789240058934-eng.pdf."},{"key":"ref_156","unstructured":"Global Polio Eradication Initiative (2023, November 13). 2022 Annual Report. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2023\/06\/GPEI_2022_Expenditure_Report.pdf."},{"key":"ref_157","unstructured":"Polio Oversight Board (2023, April 10). Meeting of the Polio Oversight Board, Global Polio Eradication Initiative, 12 December 2014. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/POB_Minutes_Mtg20141212.pdf."},{"key":"ref_158","unstructured":"Polio Oversight Board (2023, April 10). Meeting of the Polio Oversight Board (Call), 13 January 2016. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/POB_Minutes_Mtg20160113.pdf."},{"key":"ref_159","unstructured":"Polio Oversight Board (2024, April 10). Meeting of the Polio Oversight Board (POB)\u2014Teleconference, 18 December 2020. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2021\/02\/POB-minutes-20201218.pdf."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1017\/S095026881900181X","article-title":"Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters","volume":"147","author":"Kalkowska","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"ref_161","unstructured":"Global Polio Eradication Initiative, and World health organization (2019). Polio Endgame Strategy 2019\u20132023: Eradication, Integration, Certification and Containment, World Health Organization."},{"key":"ref_162","unstructured":"Global Polio Eradication Initiative (2018). Polio Post-Certification Strategy: A Risk Mitigation Strategy for a Polio-Free World, World Health Organization."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Duintjer Tebbens, R.J., Pallansch, M.A., Cochi, S.L., Wassilak, S.G.F., and Thompson, K.M. (2015). An economic analysis of poliovirus risk management policy options for 2013\u20132052. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1112-8"},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Duintjer Tebbens, R.J., Pallansch, M.A., Wassilak, S.G., Cochi, S.L., and Thompson, K.M. (2016). Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1465-7"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/risa.12962","article-title":"Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations","volume":"38","author":"Pallansch","year":"2018","journal-title":"Risk Anal."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/risa.13193","article-title":"Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/risa.13214","article-title":"Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan","volume":"39","author":"Kalkowska","year":"2019","journal-title":"Risk Anal."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/risa.13194","article-title":"Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan","volume":"39","author":"Thompson","year":"2019","journal-title":"Risk Anal."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"African Regional Commission for the Certification of Poliomyelitis Eradication (2020). Certifying the interruption of wild poliovirus transmission in the WHO African region on the turbulent journey to a polio-free world. Lancet Glob. Health, 8, e1345\u2013e1351.","DOI":"10.1016\/S2214-109X(20)30382-X"},{"key":"ref_170","unstructured":"World Health Organization (2019, December 31). Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication, Geneva, Switzerland, 17\u201318 October 2019. Available online: http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/20th-meeting-of-the-Global-Commission-for-the-Certification-of-Eradication-of-Poliomyelitis-17-18-October-2019.pdf."},{"key":"ref_171","unstructured":"Global Polio Eradication Initiative, and World Health Organization (2020). Strategy for the Response to Type 2 Circulating Vaccine-Derived Poliovirus 2020\u20132021: An Addendum to the Polio Endgame Strategy 2019-2023, World Health Organization."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","article-title":"Economic analysis of the Global Polio Eradication Initiative","volume":"29","author":"Pallansch","year":"2010","journal-title":"Vaccine"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.abc4262","article-title":"Can existing live vaccines prevent COVID-19?","volume":"368","author":"Chumakov","year":"2020","journal-title":"Science"},{"key":"ref_174","unstructured":"Gallo, R., and Arbess, D.J. (2020, July 01). An Old Vaccine May Help against Coronavirus: A Tablet for Polio Boosts Innate Immunity, Which Fights Other Viruses. Available online: https:\/\/www.wsj.com\/articles\/an-old-vaccine-may-help-against-coronavirus-11593557168."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/risa.13671","article-title":"No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]","volume":"41","author":"Thompson","year":"2021","journal-title":"Risk Anal."},{"key":"ref_176","unstructured":"Global Polio Eradication Initiative, and World Health Organization (2021). Polio Eradication Strategy 2022\u20132026: Delivering on a Promise, World Health Organization."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(07)60532-7","article-title":"Eradication versus control for poliomyelitis: An economic analysis","volume":"369","author":"Thompson","year":"2007","journal-title":"Lancet"},{"key":"ref_178","unstructured":"World Health Organization (2022, September 12). Report from the Twenty-Second Meeting of the Global Commission for Certification of Poliomyelitis Eradication, Geneva, Switzerland, 3 June 2022. Available online: https:\/\/polioeradication.org\/wp-content\/uploads\/2022\/09\/22nd-GCC-report-20220907.pdf."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.15585\/mmwr.mm7249a3","article-title":"Use of inactivated polio vaccine among U.S. qdults: Updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023","volume":"72","author":"Kidd","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jtbi.2005.04.017","article-title":"Modeling polio as a disease of development","volume":"237","author":"Stone","year":"2005","journal-title":"J. Theor. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/aje\/kwi206","article-title":"A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future","volume":"162","author":"Pallansch","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"ref_182","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson","year":"2008","journal-title":"Medscape J. Med."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2105\/AJPH.2007.122192","article-title":"The risks, costs, and benefits of possible future global policies for managing polioviruses","volume":"98","author":"Thompson","year":"2008","journal-title":"Am. J. Public Health"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.1130388","article-title":"New strategies for the elimination of polio from India","volume":"314","author":"Grassly","year":"2006","journal-title":"Science"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0140-6736(07)60531-5","article-title":"Protective efficacy of a monovalent oral type 1 poliovirus vaccine: A case-control study","volume":"369","author":"Grassly","year":"2007","journal-title":"Lancet"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJMoa0803259","article-title":"Effectiveness of immunization against paralytic poliomyelitis in Nigeria","volume":"359","author":"Jenkins","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1056\/NEJMoa0910074","article-title":"Implications of a circulating vaccine-derived poliovirus in Nigeria","volume":"326","author":"Jenkins","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_188","first-page":"561","article-title":"Projection of costs of polio eradication compared to permanent control","volume":"221","author":"Zimmermann","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_189","unstructured":"Global Polio Eradication Initiative (2022). Investment Case 2022\u20132026, World Health Organization."},{"key":"ref_190","unstructured":"World Health Organization (2005). Status of polio outbreaks in 2005. Polio Erad. Initiat.\u2014Polio News, 25, 2\u20133."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1539-6924.2006.00843.x","article-title":"Evaluation of response scenarios to potential polio outbreaks using mathematical models","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/j.1539-6924.2006.00853.x","article-title":"Poliomyelitis and the role of risk analysis in global infectious disease policy and management","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/j.1539-6924.2006.00844.x","article-title":"Containment of polioviruses after eradication and OPV cessation: Characterizing risks to improve management","volume":"26","author":"Dowdle","year":"2006","journal-title":"Risk Anal."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1539-6924.2006.00827.x","article-title":"Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication","volume":"26","author":"Pallansch","year":"2006","journal-title":"Risk Anal."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/infdis\/jis241","article-title":"Waning intestinal immunity after vaccination with oral poliovirus vaccines in India","volume":"205","author":"Grassly","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/infdis\/jit845","article-title":"Modeling the dynamics of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Pons-Salort, M., Molodecky, N.A., O\u2019Reilly, K.M., Wadood, M.Z., Safdar, R.M., Etsano, A., Vaz, R.G., Jafari, H., Grassly, N.C., and Blake, I.M. (2016). Population immunity against serotype-2 poliomyelitis leading up to the global withdrawal of the oral poliovirus vaccine: Spatio-temporal modelling of surveillance data. PLOS Med., 13.","DOI":"10.1371\/journal.pmed.1002140"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1093\/infdis\/jit601","article-title":"Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: Systematic review and meta-analysis","volume":"210","author":"Grassly","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fimmu.2017.01103","article-title":"Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: An analysis of the World Health Organization registry","volume":"8","author":"Macklin","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/S1473-3099(17)30358-4","article-title":"Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: An open-label cluster-randomised trial and modelling study","volume":"17","author":"Taniuchi","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1586\/14760584.2015.1052800","article-title":"Impact of inactivated poliovirus vaccine on mucosal immunity: Implications for the polio eradication endgame","volume":"14","author":"Parker","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/aje\/kwt203","article-title":"The potential impact of routine immunization with inactivated poliovirus vaccine on wild-type or vaccine-derived poliovirus outbreaks in a posteradication setting","volume":"178","author":"Mangal","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3201\/eid2302.161210","article-title":"Estimated effect of inactivated poliovirus vaccine campaigns, Nigeria and Pakistan, January 2014\u2013April 2016","volume":"23","author":"Shirreff","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3201\/eid2411.180050","article-title":"Effect of inactivated poliovirus vaccine campaigns, Pakistan, 2014\u20132017","volume":"24","author":"Grassly","year":"2018","journal-title":"Emerg. Infect. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1539-6924.2006.00831.x","article-title":"Retrospective cost-effectiveness analyses for polio vaccination in the United States","volume":"26","author":"Thompson","year":"2006","journal-title":"Risk Anal."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1539-6924.2006.00842.x","article-title":"The costs of future polio risk management policies","volume":"26","author":"Sangrujee","year":"2006","journal-title":"Risk Anal."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1539-6924.2008.01078.x","article-title":"Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management","volume":"28","author":"Pallansch","year":"2008","journal-title":"Risk Anal."},{"key":"ref_208","first-page":"35","article-title":"Policy decision options during the first 5 years following certification of polio eradication","volume":"5","author":"Sangrujee","year":"2003","journal-title":"MedGenMed"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"S485","DOI":"10.1093\/infdis\/jit838","article-title":"Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation","volume":"210","author":"Thompson","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1093\/infdis\/jit834","article-title":"Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria","volume":"210","author":"Kalkowska","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Pons-Salort, M., Burns, C.C., Lyons, H., Blake, I.M., Jafari, H., Oberste, M.S., Kew, O.M., and Grassly, N.C. (2016). Preventing vaccine-derived poliovirus emergence during the polio endgame. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005728"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:46:25Z","timestamp":1760107585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/6\/435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":211,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["pathogens13060435"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13060435","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]}}}